| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 24,500 | 24,610 | 21:23 | |
| 24,500 | 24,620 | 21:23 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 28,090 | 75 | |||
| 27,390 | 80 | |||
| 27,050 | 112 | |||
| 26,000 | 220 | |||
| 25,800 | 19 | |||
| 25,750 | 106 | |||
| 24,640 | 136 | |||
| 24,620 | 136 | |||
| 24,600 | 1.500 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/gs71.htm [/URL] | ||||
| 669 | 24,490 | |||
| 831 | 24,480 | |||
| 136 | 24,460 | |||
| 136 | 24,440 | |||
| 100 | 15,000 | |||
| 1.062 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.934 | 0,813 | 2.384 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:58 | 24,490 | 401 |
| 17:26:42 | 24,580 | 408 |
| 17:26:19 | 24,570 | 243 |
| 17:26:19 | 24,570 | 257 |
| 17:25:29 | 24,590 | 380 |
| 17:24:28 | 24,610 | 155 |
| 17:24:26 | 24,610 | 89 |
| 17:23:42 | 24,610 | 63 |
| 17:22:41 | 24,630 | 269 |
| 17:22:20 | 24,620 | 200 |
| 17:22:14 | 24,630 | 431 |
| 17:22:04 | 24,620 | 9 |
| 17:20:08 | 24,620 | 57 |
| 17:15:51 | 24,700 | 58 |
| 17:10:19 | 24,700 | 17 |
| 17:10:19 | 24,700 | 107 |
| 17:08:12 | 24,700 | 370 |
| 17:02:01 | 24,670 | 60 |
| 17:02:01 | 24,670 | 58 |
| 16:58:58 | 24,680 | 429 |
| Tagesumsatz Xetra | -0,650 -2,59 % | 43.467 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:10 | GSK schließt Übernahme von 35Pharma für 950 Mio. US-Dollar ab und sichert sich Medikament gegen Lungenhochdruck | 4 | Investing.com Deutsch | ||
| 11:55 | GSK completes purchase of Canada's 35Pharma for USD950 million | 4 | Alliance News | ||
| GSK Aktie jetzt für 0€ handeln | |||||
| 09:06 | GSK completes $950M acquisition of Canada's 35Pharma | 5 | Investing.com | ||
| 08:58 | GSK schließt Übernahme von kanadischem Biotech-Unternehmen 35Pharma für 950 Mio. US-Dollar ab | 5 | Investing.com Deutsch | ||
| 08:12 | GSK PLC - GSK completes acquisition of 35Pharma Inc. | 1 | RNS |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 09:06 | JEFFERIES stuft NOVO NORDISK auf 'Hold' | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Novo Nordisk auf "Hold" mit einem Kursziel von 270 dänischen Kronen belassen. Die Nachfragen der US-Zulassungsbehörde FDA... ► Artikel lesen | |
| 13:42 | Tilray Brands, Inc.: Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership | GlobeNewswire (Europe) | NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.?("Tilray", "our", "we" or the "Company") (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged... ► Artikel lesen | |
| 14:10 | Teva Pharmaceutical Industries Ltd: Teva Launches Home Ground Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners | GlobeNewswire (Europe) | For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground Schizophrenia Community is a centralized destination that... ► Artikel lesen | |
| 13:06 | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications | GlobeNewswire (Europe) | Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve... ► Artikel lesen | |
| 15:04 | Wayfinder Biosciences, Inc.: Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | PR Newswire | SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today... ► Artikel lesen |